C. R. Bard | Evaluate

December 11, 2018

The FDA’s proposed changes to device regulation are thin on detail

The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require congressional approval, and could thus take years.

Boston and Coloplast sink on mesh mess

The FDA’s proposed changes to device regulation are thin on detail

Luck, strategy and FDA device approvals

Interview – Serial acquirer Teleflex seeks deals both big and small

Top 20 medtechs jockey for position, but their overall share will drop

Startling reversal of fortunes as large-cap medtechs soar

Snippet roundup: Novartis enters Advair generic race, Biogen dealt CFO blow

The return of medtech scale-building?

Political ructions, poor deal-making and scandal – a bad year for big-cap medtechs

Sun comes out for big-cap medtechs as investors seek refuge from market squalls

Medtech news over the Christmas period

Latest Reports

Genetic Medicine: The Next Generation

PD(L)anner - March 2022

Editor's Picks

Bristol needs to get fresh

The next generation of diabetes technology

Nkarta: at least as good as Fate, at a tenth of the price

How Gal appointment could influence strategy at Novartis

US FDA approval tracker: April